Outcomes with the addition of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management of both systolic and diastolic HF patients have demonstrated decreased cardiovascular mortality and readmission rate (3). Here, SLC5A2 is linked to hydrops fetalis.